Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
RYTELO (IMETELSTAT SODIUM) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
RYTELO
NDA
Get alerts
IMETELSTAT SODIUM | N217779 | GERON CORP
2 strengths
6 unique patents
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
6 unique patents, 1 exclusivity by expiration date
All strengths
EQ 47MG BASE/VIAL
EQ 188MG BASE/VIAL
Expiring < 1yr (3)
Active (3)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
Today
7494982
Dec. 27, 2026
9375485
Mar. 15, 2033
9388415
Sep. 9, 2026
9388416
Sep. 9, 2026
12171778
Jun. 16, 2039
12442000
Mar. 15, 2033
ODE-482
Jun. 6, 2031
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (2)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — EQ 47MG BASE/VIAL
RLD
6 patents
1 exclusivity
▴
POWDER;INTRAVENOUS | Approved: Jun 6, 2024
Patents (6)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
7494982
Dec 27, 2026
—
Yes
Yes
—
—
9375485
Mar 15, 2033
—
—
—
U-3956
TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WITH TRANSFUSION-DEPENDENT ANEMIA
—
9388415
Sep 9, 2026
—
—
—
U-3956
TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WITH TRANSFUSION-DEPENDENT ANEMIA
—
9388416
Sep 9, 2026
—
—
—
U-3956
TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WITH TRANSFUSION-DEPENDENT ANEMIA
—
12171778
Jun 16, 2039
—
—
—
U-3956
TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WITH TRANSFUSION-DEPENDENT ANEMIA
—
12442000
Mar 15, 2033
—
—
—
U-3956
TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WITH TRANSFUSION-DEPENDENT ANEMIA
—
Exclusivities (1)
Code
Date
Status
ODE-482
Jun 6, 2031
Active
#002 — EQ 188MG BASE/VIAL
RLD
6 patents
1 exclusivity
▾
POWDER;INTRAVENOUS | Approved: Jun 6, 2024